Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Ruxolitinib (Jakavi®)	TA289 - Ruxolitinib for disease-related splenomegaly or symptoms in adults with myelofibrosis TA921: Ruxolitinib for treating polycythaemia vera
Sacituzumab govitecan	TA819: Sacituzumab govitecan for treating unresectable triple-negative advanced breast cancer after 2 or more therapies
Sacubitril/Valsartan (Entresto®)	TA388 - Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction	RICaD. Transfer to primary care at three months following initiation by Heart Failure specialist supported by a RICaD.
Sapropterin dihydrochloride (Kuvan)	TA729 - Sapropterin for treating hyperphenylalaninaemia in phenylketonuria
Sarilumab	TA485 - Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab	TA350 - Secukinumab for treating moderate to severe plaque psoriasis TA719 - Secukinumab for treating non-radiographic axial spondyloarthritis TA734 - Secukinumab for treating moderate to severe plaque psoriasis in children and young people TA935 - Secukinumab for treating moderate to severe hidradenitis suppurativa
Selpercatinib (Retsevmo®)	TA760 - Selpercatinib for previously treated RET fusion-positive advanced non-small cell lung cancer TA911 - Selpercatinib for untreated RET fusion-positive advanced non-small-cell lung cancer
Semaglutide (Wegovy®)	TA875 - Semaglutide for managing overweight and obesity	The use of semaglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place. Prescribe by brand (Wegovy®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes. The Wegovy® brand of semaglutide is not commercially available yet.
Siponimod (Mayzent®)	TA656 - Siponimod for treating secondary progressive multiple sclerosis
Sirolimus solution	TA85 - Immunosuppressive therapy for renal transplantation in adults	New post-transplant

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.